Published in J Clin Oncol on November 01, 2005
Repeating blood cultures in neutropenic children with persistent fevers when the initial blood culture is negative. Pediatr Blood Cancer (2012) 2.07
Hospital discharges for fever and neutropenia in pediatric cancer patients: United States, 2009. BMC Cancer (2015) 1.41
Why pediatric patients with cancer visit the emergency department: United States, 2006-2010. Pediatr Blood Cancer (2014) 0.92
Neutropenic patients and their infectious complications at a University Hospital. Rev Bras Hematol Hemoter (2013) 0.87
Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer. J Pediatr (2013) 0.85
Multidisciplinary care in pediatric oncology. J Multidiscip Healthc (2011) 0.85
Management of fever and neutropenia in children with cancer. Support Care Cancer (2014) 0.82
Clinical efficacy of adjunctive G-CSF on solid tumor and lymphoma patients with established febrile neutropenia. Support Care Cancer (2013) 0.81
Protocol for a systematic review of reductions in therapy for children with low-risk febrile neutropenia. Syst Rev (2014) 0.79
Factors associated with hospital length of stay among cancer patients with febrile neutropenia. PLoS One (2014) 0.78
Incidence and impact of baseline electrolyte abnormalities in patients admitted with chemotherapy induced febrile neutropenia. J Cancer (2011) 0.77
Systematic review of reduced therapy regimens for children with low risk febrile neutropenia. Support Care Cancer (2016) 0.77
Clinical relevance of molecular identification of microorganisms and detection of antimicrobial resistance genes in bloodstream infections of paediatric cancer patients. BMC Infect Dis (2016) 0.75
Comparison of Antimicrobial Sensitivity to Older and Newer Quinolones versus Piperacillin-Tazobactam, Cefepime and Meropenem in Febrile Patients with Cancer in two Referral Pediatric Centers in Tehran, Iran. Mediterr J Hematol Infect Dis (2014) 0.75
Bacterial bloodstream infections and antimicrobial susceptibility pattern in pediatric hematology/oncology patients after anticancer chemotherapy. Infect Drug Resist (2014) 0.75
Antibiotic-Resistant Gram-Negative Bacteremia in Febrile Neutropenic Children. Infect Chemother (2016) 0.75
Can complications in febrile neutropenia be predicted? Report from a developing country. Support Care Cancer (2017) 0.75
Effect of Nigella sativa seed administration on prevention of febrile neutropenia during chemotherapy among children with brain tumors. Childs Nerv Syst (2017) 0.75
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 5.03
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2012) 4.42
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol (2007) 4.06
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03
Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer (2006) 3.86
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med (2004) 3.50
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer (2007) 3.27
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer (2004) 3.15
Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol (2003) 2.88
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw (2011) 2.73
American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol (2006) 2.68
Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer (2011) 2.67
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care (2005) 2.37
Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys (2003) 2.28
Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med (2005) 2.25
Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer (2005) 2.20
Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol (2006) 2.17
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol (2005) 2.13
The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion (2007) 2.12
QRS duration and mortality in patients with congestive heart failure. Am Heart J (2002) 2.10
Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (2006) 2.03
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02
Clinical application of asparaginase activity levels following treatment with pegaspargase. Pediatr Blood Cancer (2014) 1.99
Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys (2008) 1.95
Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol (2007) 1.92
Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer (2010) 1.91
Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis (2011) 1.85
Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med (2008) 1.85
Randomized controlled trial to improve care for urban children with asthma: results of the School-Based Asthma Therapy trial. Arch Pediatr Adolesc Med (2011) 1.79
American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol (2008) 1.75
Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res (2010) 1.66
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw (2008) 1.65
Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol (2006) 1.65
Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer (2011) 1.62
Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003-2004 and 2004-2005 influenza seasons. Pediatrics (2008) 1.56
Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries. J Natl Cancer Inst (2009) 1.56
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol (2012) 1.56
In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res (2004) 1.55
A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer (2007) 1.54
Parental beliefs about medications and medication adherence among urban children with asthma. Ambul Pediatr (2005) 1.53
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol (2010) 1.52
Short communication: risk of elevated total cholesterol/high-density lipoprotein cholesterol ratio after antiretroviral therapy in HIV/hepatitis C virus patients. AIDS Res Hum Retroviruses (2012) 1.40
P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck (2003) 1.40
Predictors of skin self-examination performance. Cancer (2002) 1.39
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39
Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care (2008) 1.39
Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol (2007) 1.37
Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope (2002) 1.35
Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck (2002) 1.32
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol (2012) 1.32
Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol (2008) 1.27
Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med (2014) 1.27
Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat (2006) 1.25
Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol (2008) 1.24
Undertreatment of cancer patients with chemotherapy is a global concern. J Oncol Pract (2008) 1.23
Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 1.23
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol (2009) 1.21
Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2007) 1.19
Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol (2003) 1.19
Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol (2002) 1.16
Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer (2004) 1.16
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health (2008) 1.14
Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw (2011) 1.14
Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw (2003) 1.14
Skin cancer awareness in suburban employees: a Hispanic perspective. J Am Acad Dermatol (2002) 1.13
Myeloid growth factors. J Natl Compr Canc Netw (2013) 1.13
American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol (2012) 1.12
Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol (2011) 1.12
Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer (2007) 1.11
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer (2011) 1.10
ASCO Clinical Practice Guidelines: Past, Present and Future. J Oncol Pract (2008) 1.10
Mobile crisis team intervention to enhance linkage of discharged suicidal emergency department patients to outpatient psychiatric services: a randomized controlled trial. Acad Emerg Med (2009) 1.10
Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck (2002) 1.06
Costs associated with febrile neutropenia in the US. Pharmacoeconomics (2012) 1.06
Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol (2012) 1.04
Gender differences in mortality in patients with severe sepsis or septic shock. Gend Med (2010) 1.04
Myeloid growth factors. J Natl Compr Canc Netw (2011) 1.03
Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med (2014) 1.03
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genet Med (2012) 1.03
Antiemetics: american society of clinical oncology clinical practice guideline update. J Oncol Pract (2011) 1.02
Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer (2009) 1.02
Thyroid cancer risk 40+ years after irradiation for an enlarged thymus: an update of the Hempelmann cohort. Radiat Res (2010) 1.01
Integration of the Case-Based Series in Population-Oriented Prevention into a problem-based medical curriculum. Am J Prev Med (2003) 1.01
Vitamin D and non-Hodgkin lymphoma risk in adults: a review. Cancer Invest (2009) 1.00
The effect of modafinil on cognitive function in breast cancer survivors. Cancer (2009) 1.00
Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer (2013) 0.99
Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. J Natl Cancer Inst (2013) 0.98
Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv (2006) 0.97
Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood (2009) 0.97
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J Natl Compr Canc Netw (2008) 0.96